Cargando…
The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink
BACKGROUND: There are few recent studies on the use of 5-aminosalicylates (5-ASA) as therapy for Crohn’s disease (CD) in routine clinical practice. The aim of this database investigation was to provide real-world evidence on 5-ASA use in CD. METHODS: Patients with CD, aged ≥18 years when first presc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406809/ https://www.ncbi.nlm.nih.gov/pubmed/32879597 http://dx.doi.org/10.20524/aog.2020.0521 |
_version_ | 1783567489757609984 |
---|---|
author | Hart, Ailsa Ng, Siew C. Watkins, John Paridaens, Kristine Edwards, James O. Fullarton, John R. Sonderegger, Yum Lina Yip Ghatnekar, Ola Ghosh, Subrata |
author_facet | Hart, Ailsa Ng, Siew C. Watkins, John Paridaens, Kristine Edwards, James O. Fullarton, John R. Sonderegger, Yum Lina Yip Ghatnekar, Ola Ghosh, Subrata |
author_sort | Hart, Ailsa |
collection | PubMed |
description | BACKGROUND: There are few recent studies on the use of 5-aminosalicylates (5-ASA) as therapy for Crohn’s disease (CD) in routine clinical practice. The aim of this database investigation was to provide real-world evidence on 5-ASA use in CD. METHODS: Patients with CD, aged ≥18 years when first prescribed 5-ASA (index date) and having received 5-ASA at any time between 01 January 2006 and 07 May 2018, were included for analysis. Outcomes included treatment patterns and resource use. RESULTS: Of 21,456 patients with CD, 9492 (44.2%) had been prescribed 5-ASA, with the majority (5606; 59.1%) starting on oral 5-ASA as monotherapy. 58.3% (5537) of patients on 5-ASA did not require dose change, 67.6% (6416) did not require supplementary treatment (e.g., corticosteroids, immunosuppressants, etc.), and 4.6% (436) required a switch to another treatment. Resource use was significantly decreased in the year after vs. year before 5-ASA initiation (including: specialist referrals, hospitalizations and hospital days; all P<0.001). Patients remained on 5-ASA for a median of 4.7 years (interquartile range 1.2-10.1). 25.3% (2406) of patients were still on 5-ASA at 10 years. There was a significant correlation between earlier use of 5-ASA following diagnosis and longer 5-ASA retention (P<0.001). CONCLUSIONS: 5-ASA is widely used as a long-term treatment for CD, as evidenced by continuation rates extending beyond 10 years in a quarter of patients. CD-related healthcare resource use decreased significantly in the year following 5-ASA initiation. Earlier use was associated with longer retention. |
format | Online Article Text |
id | pubmed-7406809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-74068092020-09-01 The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink Hart, Ailsa Ng, Siew C. Watkins, John Paridaens, Kristine Edwards, James O. Fullarton, John R. Sonderegger, Yum Lina Yip Ghatnekar, Ola Ghosh, Subrata Ann Gastroenterol Original Article BACKGROUND: There are few recent studies on the use of 5-aminosalicylates (5-ASA) as therapy for Crohn’s disease (CD) in routine clinical practice. The aim of this database investigation was to provide real-world evidence on 5-ASA use in CD. METHODS: Patients with CD, aged ≥18 years when first prescribed 5-ASA (index date) and having received 5-ASA at any time between 01 January 2006 and 07 May 2018, were included for analysis. Outcomes included treatment patterns and resource use. RESULTS: Of 21,456 patients with CD, 9492 (44.2%) had been prescribed 5-ASA, with the majority (5606; 59.1%) starting on oral 5-ASA as monotherapy. 58.3% (5537) of patients on 5-ASA did not require dose change, 67.6% (6416) did not require supplementary treatment (e.g., corticosteroids, immunosuppressants, etc.), and 4.6% (436) required a switch to another treatment. Resource use was significantly decreased in the year after vs. year before 5-ASA initiation (including: specialist referrals, hospitalizations and hospital days; all P<0.001). Patients remained on 5-ASA for a median of 4.7 years (interquartile range 1.2-10.1). 25.3% (2406) of patients were still on 5-ASA at 10 years. There was a significant correlation between earlier use of 5-ASA following diagnosis and longer 5-ASA retention (P<0.001). CONCLUSIONS: 5-ASA is widely used as a long-term treatment for CD, as evidenced by continuation rates extending beyond 10 years in a quarter of patients. CD-related healthcare resource use decreased significantly in the year following 5-ASA initiation. Earlier use was associated with longer retention. Hellenic Society of Gastroenterology 2020 2020-06-22 /pmc/articles/PMC7406809/ /pubmed/32879597 http://dx.doi.org/10.20524/aog.2020.0521 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hart, Ailsa Ng, Siew C. Watkins, John Paridaens, Kristine Edwards, James O. Fullarton, John R. Sonderegger, Yum Lina Yip Ghatnekar, Ola Ghosh, Subrata The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title_full | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title_fullStr | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title_full_unstemmed | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title_short | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink |
title_sort | use of 5-aminosalicylates in crohn’s disease: a retrospective study using the uk clinical practice research datalink |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406809/ https://www.ncbi.nlm.nih.gov/pubmed/32879597 http://dx.doi.org/10.20524/aog.2020.0521 |
work_keys_str_mv | AT hartailsa theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ngsiewc theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT watkinsjohn theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT paridaenskristine theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT edwardsjameso theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT fullartonjohnr theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT sondereggeryumlinayip theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ghatnekarola theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ghoshsubrata theuseof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT hartailsa useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ngsiewc useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT watkinsjohn useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT paridaenskristine useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT edwardsjameso useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT fullartonjohnr useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT sondereggeryumlinayip useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ghatnekarola useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink AT ghoshsubrata useof5aminosalicylatesincrohnsdiseasearetrospectivestudyusingtheukclinicalpracticeresearchdatalink |